Neurocrine Biosciences (NBIX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Neurocrine Biosciences (NBIX) Tops Q2 EPS by 10c
August 1, 2018 7:16 AM EDT
Needham & Company raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $125.00 (from $110.00) while maintaining a Buy rating.
Analyst Alan Carr commented, "Neurocrine reported $96.9M in 2Q18 Ingrezza sales, above our $85.0M and consensus $84M ests. Mgmt still not providing sales guidance, but... More
August 1, 2018 6:58 AM EDT
Baird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $131.00 (from $122.00) while maintaining an Outperform rating on continued strength in Ingrezza launch.
Analyst Brian Skorney commented, "Neurocrine reported earnings, with net sales of Ingrezza coming in well ahead of expectations at $96.9M.... More
August 1, 2018 5:38 AM EDT
Barclays raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $135.00 (from $100.00) while maintaining a Overweight rating.
...
More
